The global drug discovery services market is undergoing rapid expansion, projected to grow from USD 16.36 billion in 2025 to USD 27.23 billion by 2030, registering a CAGR of 10.7% during the forecast period. This acceleration is driven by rising R&D investments, growing demand for rare disease treatments, technological innovation, and the increasing cost and complexity of in-house drug development.

What’s Driving the Surge in the Drug Discovery Services Market?

Several converging forces are fueling the momentum of the drug discovery services market:

• Rising R&D Expenditure
  Global pharmaceutical and biopharmaceutical companies are increasing their research budgets to accelerate the development of innovative therapies, particularly for rare diseases and orphan drugs.
• High Cost of In-House Development
  The escalating costs associated with building and maintaining internal drug discovery infrastructure are driving organizations to outsource specialized services to Contract Research Organizations (CROs).
• Technological Advancements
  New drug discovery techniques such as structure-based drug design, combinatorial chemistry, and AI-driven screening are enabling more efficient target identification and lead optimization.
• Patent Expirations & Generic Competition
  The wave of patent expirations has intensified the need for faster, cost-effective drug pipelines, pushing companies to partner with experienced CROs to compress timelines and maximize return on investment.
• Specialized Testing and Regulatory Complexity
  With increasing regulatory scrutiny, analytical testing outsourcing has grown significantly. CROs bring specialized expertise that allows pharmaceutical companies to stay compliant while focusing on core competencies.

Download PDF Brochure

Who Are the Key Players Leading the Market Transformation?

The drug discovery services market is dominated by a few global leaders who have strategically expanded their capabilities through organic growth, acquisitions, partnerships, and geographic expansion.

1. Thermo Fisher Scientific Inc. (US)

Thermo Fisher has established itself as a fully integrated drug discovery partner, with operations spanning over 150 countries. In 2024, its Life Sciences Solutions segment generated over USD 14 billion in revenue.

• In June 2024, Thermo Fisher expanded its central lab operations in Kentucky to accelerate the delivery of medicines.
• In November 2024, the company launched Accelerator Drug Development, expanding its CRO and CDMO services.
• A new 72,500 sq. ft. clinical research laboratory in Wisconsin expanded its chemistry, manufacturing, and control (CMC) analytical capabilities, strengthening its clinical development infrastructure.

2. Charles River Laboratories (US)

Charles River is a leading CRO offering a comprehensive portfolio of drug discovery and early-stage development services.

• In February 2024, it merged with Wheeler Bio to integrate a CMC platform, enhancing its discovery and safety assessment division.
• In January 2025, Charles River partnered with NJ Bio, combining end-to-end ADC (Antibody Drug Conjugate) discovery services with bioconjugation and manufacturing capabilities.
• Earlier, in 2023, it acquired SAMDI Tech to bolster high-throughput screening (HTS) capabilities.

3. WuXi AppTec (China)

WuXi AppTec operates across the US, China, Germany, Iceland, Israel, and Korea. Known for rapid capacity expansion, it focuses on maintaining high service quality while adapting to innovative market shifts.

• In July 2022, WuXi announced USD 1.43 billion investment to build a new R&D and manufacturing facility in Singapore.
• Its Lab Testing Division has consistently expanded toxicological capacity to support global drug development.

4. Pharmaron (China)

Pharmaron offers fully integrated drug discovery and development services, from target identification to preclinical candidate selection.

• Its acquisition of the Commercial API Manufacturing Facility in the UK from Recipharm in 2022 enhanced its end-to-end chemistry and manufacturing service offerings.
• Pharmaron is leveraging both organic expansion and inorganic acquisitions to strengthen its position in Europe and Asia.

Where Are the Key Market Opportunities Emerging?

1. Chemistry Services Segment Leading the Way

The chemistry services segment dominated the drug discovery services market in 2024.

• Technologies like combinatorial chemistry and structure-based drug design are accelerating lead identification and optimization.
• The demand for high-quality, safe, and effective drugs continues to drive growth in analytical chemistry services.

2. Biologics Segment Showing Fastest Growth

Within the drug type segment, biologics are the fastest-growing.

• Biopharma companies are focusing on biologics to address complex diseases, but challenges like high development costs, manufacturing complexity, and regulatory hurdles are prompting outsourcing to experienced CROs.
• End-to-end biologics discovery services are becoming a strategic differentiator for CROs.

3. Asia Pacific: The Next Frontier

The Asia Pacific region is expected to grow at a significant CAGR between 2025 and 2030.

• Factors include less stringent regulations, expanding pharmaceutical industries, and a growing number of CROs.
• China and India are emerging as cost-efficient innovation hubs, attracting outsourcing from North America and Europe.

Why This Market Matters Strategically for C-Level Leaders

For senior executives, the drug discovery services market offers three clear strategic advantages:

• Accelerated Time-to-Market
  Outsourcing allows companies to shorten R&D cycles, improving pipeline velocity in highly competitive therapeutic areas.
• Enhanced ROI through Operational Efficiency
  CRO partnerships enable pharmaceutical companies to reduce fixed infrastructure costs, optimize resource allocation, and focus on core R&D innovation.
• Global Access to Innovation
  Leading CROs bring geographically distributed capabilities, giving pharma firms access to specialized expertise, regulatory know-how, and new patient pools across regions.

Request Sample Report

When Should Leaders Act? — The Time Is Now

With the market projected to grow by over USD 10 billion in just five years, delaying engagement with top-tier CROs could mean missed opportunities for competitive advantage. Companies that strategically partner, invest, or expand into this space today will be positioned to lead in the next wave of biopharmaceutical innovation.

Key Takeaways for C-Suite Executives

• 📈 Rapid Market Expansion: The drug discovery services market will reach USD 27.23 billion by 2030, driven by outsourcing demand, innovation, and regulatory complexity.
• 🌐 Strategic Partnerships: Leaders like Thermo Fisher, Charles River, WuXi AppTec, and Pharmaron are shaping the market through expansion, M&A, and integrated services.
• 💡 Segment Opportunities: Chemistry services dominate today; biologics outsourcing is the fastest-growing segment.
• 🌏 Regional Advantage: Asia Pacific offers cost efficiencies and regulatory flexibility, making it a hotspot for CRO expansion.
• 🕒 Action Imperative: Early strategic moves in outsourcing and partnerships will yield long-term competitive and financial returns.

Conclusion The drug discovery services market is more than a supporting function—it’s a strategic growth engine for biopharma. As R&D costs rise and timelines compress, outsourcing to trusted CROs offers the scalability, innovation, and global reach required to stay ahead. For C-level executives, engaging with this market today is a boardroom-level decision that can shape future competitive advantage.